Literature DB >> 35999275

Efficacy and acceptability of psychosocial interventions in schizophrenia: systematic overview and quality appraisal of the meta-analytic evidence.

Marco Solmi1,2,3,4,5,6, Giovanni Croatto7, Giada Piva7, Stella Rosson7, Paolo Fusar-Poli5,8,9,10, Jose M Rubio11, Andre F Carvalho12, Eduard Vieta13, Celso Arango14, Nicole R DeTore15,16, Elizabeth S Eberlin17, Kim T Mueser17,18,19, Christoph U Correll20,21,22,23.   

Abstract

Psychosocial interventions are recommended in schizophrenia and first-episode psychosis/early psychosis (EP). Nevertheless, literature is heterogeneous and often contradictory. We conducted an umbrella review of (network) meta-analyses of randomized controlled trials (RCTs) comparing psychosocial interventions vs treatment as usual (TAU)/active interventions(ACTIVE)/MIXED controls. Primary outcome was total symptoms (TS); secondary outcomes were positive/negative/depressive symptoms (PS/NS/DS), cognition, functioning, relapse, hospitalization, quality of life (QoL), treatment discontinuation. Standardized mean difference (SMD)/odds ratio (OR)/risk ratio (RR) vs TAU/ACTIVE/MIXED were summarized at end-of-treatment (EoT)/follow-up (FU). Quality was rated as high/medium/low (AMSTAR-PLUS). Eighty-three meta-analyses were included (RCTs = 1246; n = 84,925). Against TAU, regarding TS, Early Intervention Services (EIS) were superior EoT/FU in EP (SMD = -0.32/-0.21), cognitive behavioral therapy (CBT) in schizophrenia EoT/FU (SMD = -0.38/-0.19). Regarding secondary outcomes, in EP, EIS were superior for all outcomes EoT except cognition, and at FU for PS/NS/QoL, specific family interventions (FI-s) prevented relapse EoT; in schizophrenia, superiority emerged EoT for CBT for PS/NS/relapse/functioning/QoL; psychoeducation (EDU)/any FI for relapse; cognitive remediation therapy (CRT) for cognition/functioning; and hallucination-focused integrative treatment for PS. Against ACTIVE, in EP, mixed family interventions (FI-m) were superior at FU regarding TS (SMD = -0.61) and for functioning/relapse among secondary outcomes. In schizophrenia, regarding TS, mindfulness and social skills training (SST) were superior EoT, CBT at FU; regarding secondary outcomes superiority emerged at EoT for computerized cognitive drill-and-practice training for PS/DS, CRT for cognition/functioning, EDU for relapse, individual placement and support (IPS) for employment; and at FU CBT for PS/NS. Against MIXED, in schizophrenia, CRT/EDU were superior for TS EoT (d = -0.14/SMD = -0.33), CRT regarding secondary outcomes EoT for DS/social functioning, both EoT/FU for NS/cognition/global functioning; compensatory cognitive interventions for PS/functioning EoT/FU and NS EoT; CBT for PS at FU, and EDU/SST for relapse EoT. In conclusion, mental health services should consider prioritizing EIS/any FI in EP and CBT/CRT/any FI/IPS for schizophrenia, but other interventions may be helpful for specific outcomes.
© 2022. The Author(s), under exclusive licence to Springer Nature Limited.

Entities:  

Year:  2022        PMID: 35999275     DOI: 10.1038/s41380-022-01727-z

Source DB:  PubMed          Journal:  Mol Psychiatry        ISSN: 1359-4184            Impact factor:   13.437


  86 in total

1.  What is the risk-benefit ratio of long-term antipsychotic treatment in people with schizophrenia?

Authors:  Christoph U Correll; Jose M Rubio; John M Kane
Journal:  World Psychiatry       Date:  2018-06       Impact factor: 49.548

Review 2.  Canadian Treatment Guidelines on Psychosocial Treatment of Schizophrenia in Adults.

Authors:  Ross Norman; Tania Lecomte; Donald Addington; Elizabeth Anderson
Journal:  Can J Psychiatry       Date:  2017-07-13       Impact factor: 4.356

Review 3.  A systematic review and meta-analysis of recovery in schizophrenia.

Authors:  Erika Jääskeläinen; Pauliina Juola; Noora Hirvonen; John J McGrath; Sukanta Saha; Matti Isohanni; Juha Veijola; Jouko Miettunen
Journal:  Schizophr Bull       Date:  2012-11-20       Impact factor: 9.306

4.  Royal Australian and New Zealand College of Psychiatrists clinical practice guidelines for the management of schizophrenia and related disorders.

Authors:  Cherrie Galletly; David Castle; Frances Dark; Verity Humberstone; Assen Jablensky; Eóin Killackey; Jayashri Kulkarni; Patrick McGorry; Olav Nielssen; Nga Tran
Journal:  Aust N Z J Psychiatry       Date:  2016-05       Impact factor: 5.744

5.  20-year follow-up study of physical morbidity and mortality in relationship to antipsychotic treatment in a nationwide cohort of 62,250 patients with schizophrenia (FIN20).

Authors:  Heidi Taipale; Antti Tanskanen; Juha Mehtälä; Pia Vattulainen; Christoph U Correll; Jari Tiihonen
Journal:  World Psychiatry       Date:  2020-02       Impact factor: 49.548

6.  Years of potential life lost and life expectancy in schizophrenia: a systematic review and meta-analysis.

Authors:  Carsten Hjorthøj; Anne Emilie Stürup; John J McGrath; Merete Nordentoft
Journal:  Lancet Psychiatry       Date:  2017-02-22       Impact factor: 27.083

Review 7.  Efficacy of 42 Pharmacologic Cotreatment Strategies Added to Antipsychotic Monotherapy in Schizophrenia: Systematic Overview and Quality Appraisal of the Meta-analytic Evidence.

Authors:  Christoph U Correll; Jose M Rubio; Gabriella Inczedy-Farkas; Michael L Birnbaum; John M Kane; Stefan Leucht
Journal:  JAMA Psychiatry       Date:  2017-07-01       Impact factor: 21.596

Review 8.  The 2009 schizophrenia PORT psychosocial treatment recommendations and summary statements.

Authors:  Lisa B Dixon; Faith Dickerson; Alan S Bellack; Melanie Bennett; Dwight Dickinson; Richard W Goldberg; Anthony Lehman; Wendy N Tenhula; Christine Calmes; Rebecca M Pasillas; Jason Peer; Julie Kreyenbuhl
Journal:  Schizophr Bull       Date:  2009-12-02       Impact factor: 9.306

Review 9.  Canadian Practice Guidelines for Comprehensive Community Treatment for Schizophrenia and Schizophrenia Spectrum Disorders.

Authors:  Donald Addington; Elizabeth Anderson; Martina Kelly; Alain Lesage; Chris Summerville
Journal:  Can J Psychiatry       Date:  2017-09       Impact factor: 4.356

10.  Development of AMSTAR: a measurement tool to assess the methodological quality of systematic reviews.

Authors:  Beverley J Shea; Jeremy M Grimshaw; George A Wells; Maarten Boers; Neil Andersson; Candyce Hamel; Ashley C Porter; Peter Tugwell; David Moher; Lex M Bouter
Journal:  BMC Med Res Methodol       Date:  2007-02-15       Impact factor: 4.615

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.